During the past decade, Chattanooga's Program in Women's Oncology conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 11 clinical trials were completed, i.e. on average, 137.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 6 clinical trials were completed. i.e. 120% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chattanooga's Program in Women's Oncology" #1 sponsor was "Gynecologic Oncology Group" with 7 trials, followed by "GOG Foundation" with 4 trials sponsored, "Morphotek" with 2 trials sponsored, "National Cancer Institute (NCI)" with 2 trials sponsored and "Accelerated Community Oncology Research Network" with 2 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chattanooga's Program in Women's Oncology" #1 collaborator was "National Cancer Institute (NCI)" with 10 trials as a collaborator, "Advanced Clinical Research Services, LLC" with 1 trials as a collaborator, "Akesobio Australia Pty Ltd" with 1 trials as a collaborator, "Celgene Corporation" with 1 trials as a collaborator and "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Chattanooga's Program in Women's Oncology" are "Ovarian Cancer" (8 trials), "Fallopian Tube Cancer" (4 trials), "Cervical Cancer" (3 trials), "Endometrial Clear Cell Adenocarcinoma" (3 trials) and "Endometrial Serous Adenocarcinoma" (3 trials). Many other conditions were trialed in "Chattanooga's Program in Women's Oncology" in a lesser frequency.

Most popular intervention types in "Chattanooga's Program in Women's Oncology" are "Drug" (25 trials), "Other" (12 trials), "Biological" (4 trials), "Procedure" (3 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (8 trials), "Paclitaxel" (8 trials), "Quality-of-Life Assessment" (8 trials), "Carboplatin" (6 trials) and "Questionnaire Administration" (4 trials). Other intervention names were less common.

The vast majority of trials in "Chattanooga's Program in Women's Oncology" are 32 trials for "Female" genders and 1 trials for "All" genders.

Currently, there are NaN active trials in "Chattanooga's Program in Women's Oncology". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Chattanooga's Program in Women's Oncology, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Chattanooga's Program in Women's Oncology, 3 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".